Novel investigational drugs targeting IL-6 signaling for the treatment of depression
The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Elevated levels of IL-6 have been implicated in the pathophysiology and treatment of major depressive disorder (MDD). Convergent evidence suggests that IL-6 primarily mediates proinflammatory functions via the soluble IL-6 receptor/trans-signaling, and anti-inflammatory functions via a transmembrane receptor (IL-6R). A targeted approach to selectively inhibit IL-6 trans-signaling may offer putative antidepressant effects. AREAS COVERED: This review addresses three primary domains. The first focuses on the biological role of IL-6 within inflammation and its signal transduction pathways. The second addresses the potential contributions of IL-6 to the pathophysiology of MDD, and the mechanisms that may mediate these effects. Finally, the article outlines the therapeutic benefits of incorporating anti-inflammatory properties into the pharmacological treatment of MDD, and proposes inhibition of IL-6 signaling as a viable treatment strategy. EXPERT OPINION: To improve drug development for the treatment of MDD, there is a critical need to identify promising targets. Target identification will require guidance from a strategic framework such as The Research Domain Criteria, and convincing evidence relating known targets to brain function under both physiological and pathological conditions. Although current evidence provides rationale for administering anti-IL-6 treatments in MDD, further studies confirming safety, target affinity and therapeutic benefits are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212 · cited 6×
“These kinases activate the transcription factor STAT3 via phosphorylation, which results in the translocation of STAT3 into the nucleus to initiate gene expression [22,23].”
BackgroundInfluentialCytokines sing the blues: inflammation and the pathogenesis of depression
Raison, C. L., Capuron, L., & Miller, A. H. (2006) · Trends in Immunology · doi:10.1016/j.it.2005.11.006 · Cited by 3,009
Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.
Howren, M. B., Lamkin, D. M., & Suls, J. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181907c1b · Cited by 2,766
Interleukin-6 and the acute phase response
Heinrich, P. C., Castell, J. V., & Andus, T. (1990) · Biochemical Journal · doi:10.1042/bj2650621 · Cited by 2,734
The HPA axis in major depression: classical theories and new developments
Pariante, C. M., & Lightman, S. L. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.06.006 · Cited by 2,009
Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617 · cited 3×
“[127], which identified that previously treatment-resistant depressed patients with elevated CRP levels were more likely to respond to infliximab than were similarly depressed patients with low CRP levels.”
BackgroundResultInfluentialCytokine-Associated Emotional and Cognitive Disturbances in Humans
Reichenberg, A., Yirmiya, R., Schuld, A., Kraus, T., Haack, M., Morag, A., & Pollmächer, T. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.5.445 · Cited by 1,365 · cited 1×
“Proinflammatory cytokine activation in healthy individuals is likewise associated with disturbances in affect and cognition [53,54].”
BackgroundCytokines and major depression
Schiepers, O. J. G., Wichers, M. C., & Maes, M. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.11.003 · Cited by 1,235 · cited 2×
“The theory of cytokine-induced depression is based on the concept that proinflammatory cytokines function as neuromodulators within the CNS to produce the behavioral, neuroendocrine and neurochemical features of depressive disorders [46].”
BackgroundFerrari, A. J., Somerville, A. J., Baxter, A. J., Norman, R., Patten, S. B., Vos, T., & Whiteford, H. A. (2013) · Psychological Medicine · doi:10.1017/s0033291712001511 · Cited by 1,230 · cited 1×
“Major depressive disorder (MDD) is a highly debilitating psychiatric condition, with a global prevalence rate of ~ 4 -- 5% [1,2].”
BackgroundRose-John, S. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4989 · Cited by 1,040 · cited 5×
“The IL-6/sIL-6R complex affects a wider range of target cells such as endothelial cells, neuronal cells, osteoclasts, hematopoietic progenitor cells and embryonic stem cells [37,41].”
BackgroundInfluentialThe Relationship of Depression and Stressors to Immunological Assays: A Meta-Analytic Review
Zorrilla, E. P., Luborsky, L., McKay, J. R., Rosenthal, R., Houldin, A., Tax, A., McCorkle, R., Seligman, D. A., & Schmidt, K. (2001) · Brain, Behavior, and Immunity · doi:10.1006/brbi.2000.0597 · Cited by 995 · cited 4×
“Abnormal cytokine concentrations are a highly replicated finding in MDD, particularly elevated peripheral levels of TNF-a, IL-6 and IL-1b [16,58,61,62].”
BackgroundInfluentialMajor depressive disorder: new clinical, neurobiological, and treatment perspectives
Kupfer, D. J., Frank, E., & Phillips, M. L. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60602-8 · Cited by 894 · cited 1×
“associated with MDD [7].”
Tilg, H., Trehu, E., Atkins, M., Dinarello, C., & Mier, J. (1994) · Blood · doi:10.1182/blood.v83.1.113.113 · Cited by 817
Müller, N., Schwarz, M. J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Müller, B., Spellmann, I., Hetzel, G., Maino, K., Kleindienst, N., et al. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001805 · Cited by 794
Cytokine Production and Treatment Response in Major Depressive Disorder
Lanquillon, S. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00134-7 · Cited by 735
The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer
Naugler, W. E., & Karin, M. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.12.007 · Cited by 730 · cited 6×
“The production of IL-6 in target cells further depends on multiple transcription factors, including NF-kB, CAAT/enhancer-binding protein b and activator protein 1 [19].”
BackgroundInfluentialMauer, J., Chaurasia, B., Goldau, J., Vogt, M. C., Ruud, J., Nguyen, K. D., Theurich, S., Hausen, A. C., Schmitz, J., Brönneke, H. S., et al. (2014) · Nature Immunology · doi:10.1038/ni.2865 · Cited by 727
Ito, H., Takazoe, M., Fukuda, Y., Hibi, T., Kusugami, K., Andoh, A., Matsumoto, T., Yamamura, T., Azuma, J., & Nishimoto, N. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.012 · Cited by 636
Maes, M., Meltzer, H. Y., Bosmans, E., Bergmans, R., Vandoolaeghe, E., Ranjan, R., & Desnyder, R. (1995) · Journal of Affective Disorders · doi:10.1016/0165-0327(95)00028-l · Cited by 622 · cited 4×
“However, the anti-inflammatory effects of antidepressants are inconsistent, with some studies reporting treatment-induced elevations of IL-6 [115], while others report nonsignificant changes (Table 2) [64,116].”
BackgroundResultInfluentialSteiner, J., Walter, M., Gos, T., Guillemin, G. J., Bernstein, H.-G., Sarnyai, Z., Mawrin, C., Brisch, R., Bielau, H., zu Schwabedissen, L., et al. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-94 · Cited by 568 · cited 3×
“QUIN functions as a glutamate NMDA receptor agonist, and may contribute to the increased extracellular glutamate concentrations that are found in depression [92,99].”
BackgroundChoy, E. H. S., Isenberg, D. A., Garrood, T., Farrow, S., Ioannou, Y., Bird, H., Cheung, N., Williams, B., Hazleman, B., Price, R., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10623 · Cited by 526
Lindqvist, D., Janelidze, S., Hagell, P., Erhardt, S., Samuelsson, M., Minthon, L., Hansson, O., Björkqvist, M., Träskman-Bendz, L., & Brundin, L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.030 · Cited by 524 · cited 4×
“[73] MDD (n = 30), SCZ (n = 32), HC (n = 35) Higher cerebrospinal fluid IL-6 levels in MDD versus HC [74] [75-78]”
BackgroundMethodResultInfluentialInterferon-alpha–induced changes in tryptophan metabolism
Capuron, L., Neurauter, G., Musselman, D. L., Lawson, D. H., Nemeroff, C. B., Fuchs, D., & Miller, A. H. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00173-2 · Cited by 493
Prevalence and predictors of recurrence of major depressive disorder in the adult population
Hardeveld, F., Spijker, J., De Graaf, R., Nolen, W. A., & Beekman, A. T. F. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01519.x · Cited by 486
Deep brain stimulation for treatment-resistant depression: follow-up after 3 to 6 years
Kennedy, S. H., Giacobbe, P., Rizvi, S. J., Placenza, F. M., Nishikawa, Y., Mayberg, H. S., & Lozano, A. M. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10081187 · Cited by 481
Self-citationGrosso, G., Pajak, A., Marventano, S., Castellano, S., Galvano, F., Bucolo, C., Drago, F., & Caraci, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096905 · Cited by 449
Bonaccorso, S., Marino, V., Puzella, A., Pasquini, M., Biondi, M., Artini, M., Almerighi, C., Verkerk, R., Meltzer, H., & Maes, M. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200202000-00014 · Cited by 437
A Review of the Relationship between Proinflammatory Cytokines and Major Depressive Disorder
Young, J. J., Bruno, D., & Pomara, N. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.07.032 · Cited by 422
Baxter, A. J., Scott, K. M., Ferrari, A. J., Norman, R. E., Vos, T., & Whiteford, H. A. (2014) · Depression and Anxiety · doi:10.1002/da.22230 · Cited by 403
Tuglu, C., Kara, S. H., Caliyurt, O., Vardar, E., & Abay, E. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1566-z · Cited by 391
A prospective evaluation of the directionality of the depression–inflammation relationship
Stewart, J. C., Rand, K. L., Muldoon, M. F., & Kamarck, T. W. (2009) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2009.04.011 · Cited by 390
Frommberger, U. H., Bauer, J., Haselbauer, P., Fräulin, A., Riemann, D., & Berger, M. (1997) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02900219 · Cited by 362 · cited 1×
“Higher production of plasma IL-6 has been reported during the acute state of depressive illness [65,66], and among patients with severe depression [67] and treatmentresistant MDD [68].”
BackgroundO’Brien, S. M., Scully, P., Fitzgerald, P., Scott, L. V., & Dinan, T. G. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.05.013 · Cited by 355
Interleukin-6, a mental cytokine
Spooren, A., Kolmus, K., Laureys, G., Clinckers, R., De Keyser, J., Haegeman, G., & Gerlo, S. (2011) · Brain Research Reviews · doi:10.1016/j.brainresrev.2011.01.002 · Cited by 352
Padmos, R. C., Hillegers, M. H. J., Knijff, E. M., Vonk, R., Bouvy, A., Staal, F. J. T., de Ridder, D., Kupka, R. W., Nolen, W. A., & Drexhage, H. A. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.4.395 · Cited by 336 · cited 1×
“1 The effects of antidepressants on cytokine networks Conventional pharmacological treatments for mood disorders, including antidepressants, mood stabilizers and antipsychotics, act in varying capacities to downregulate the production of proinflammatory cytokine mRNA and protein [107-110].”
BackgroundPro- and Anti-Inflammatory Cytokine Balance in Major Depression: Effect of Sertraline Therapy
Sutcigil, L., Oktenli, C., Musabak, U., Bozkurt, A., Cansever, A., Uzun, O., Sanisoglu, S. Y., Yesilova, Z., Ozmenler, N., Ozsahin, A., et al. (2007) · Clinical and Developmental Immunology · doi:10.1155/2007/76396 · Cited by 315
Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities
Scheller, J., Garbers, C., & Rose-John, S. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2013.11.002 · Cited by 308 · cited 1×
“Soluble gp130 is present in healthy serum in the range of 250 -- 400 ng/ml, and, together with sIL-6R, forms an effective buffer to neutralize the effects of IL-6 in the blood [45].”
BackgroundThe monocyte-T-lymphocyte hypothesis of major depression
Maes, M., Smith, R., & Simon, S. (1995) · Psychoneuroendocrinology · doi:10.1016/0306-4530(94)00066-j · Cited by 299
Cytokine levels in the blood may distinguish suicide attempters from depressed patients
Janelidze, S., Mattei, D., Westrin, Å., Träskman-Bendz, L., & Brundin, L. (2011) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2010.10.010 · Cited by 298 · cited 2×
“Similar findings have been documented in other studies [74,82].”
MethodResultNery, F. G., Monkul, E. S., Hatch, J. P., Fonseca, M., Zunta‐Soares, G. B., Frey, B. N., Bowden, C. L., & Soares, J. C. (2008) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.912 · Cited by 298
Xu, Y., Ku, B., Tie, L., Yao, H., Jiang, W., Ma, X., & Li, X. (2006) · Brain Research · doi:10.1016/j.brainres.2006.09.009 · Cited by 298
Pro-inflammatory cytokines and treatment response to escitaloprsam in major depressive disorder
Eller, T., Vasar, V., Shlik, J., & Maron, E. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.09.015 · Cited by 290 · cited 1×
“Finally, high baseline levels of proinflammatory cytokines, including IL-6 and TNF-a, may also have predictive utility in determining non-response to antidepressants [118,119].”
BackgroundDysregulated relationship of inflammation and oxidative stress in major depression
Rawdin, B. J., Mellon, S. H., Dhabhar, F. S., Epel, E. S., Puterman, E., Su, Y., Burke, H. M., Reus, V. I., Rosser, R., Hamilton, S. P., et al. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.11.011 · Cited by 255 · cited 1×
“[183] Untreated MDD (n = 20), HC (n = 20) IL-6 levels positively correlated with oxidative stress marker levels in untreated MDD [184]”
BackgroundEntsuah, A. R., Huang, H., & Thase, M. E. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n1106 · Cited by 245
Sukoff Rizzo, S. J., Neal, S. J., Hughes, Z. A., Beyna, M., Rosenzweig-Lipson, S., Moss, S. J., & Brandon, N. J. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.120 · Cited by 241
A psychoneuroimmunological review on cytokines involved in antidepressant treatment response
Janssen, D. G. A., Caniato, R. N., Verster, J. C., & Baune, B. T. (2010) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1103 · Cited by 240 · cited 1×
“, IL-1b, IL-6, TNF-a and IFN-g) subsequent to depressive episode resolution [12].”
BackgroundHestad, K. A., Tønseth, S., Støen, C. D., Ueland, T., & Aukrust, P. (2003) · The Journal of ECT · doi:10.1097/00124509-200312000-00002 · Cited by 235 · cited 2×
“General anti-inflammatory effects have also been documented subsequent to the administration of cognitive behavioral therapy [14] and electroconvulsive therapy [13] in depression.”
BackgroundBull, S. J., Huezo-Diaz, P., Binder, E. B., Cubells, J. F., Ranjith, G., Maddock, C., Miyazaki, C., Alexander, N., Hotopf, M., Cleare, A. J., et al. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.48 · Cited by 228
Pathways and mechanisms for cytokine signaling of the central nervous system.
Licinio, J., & Wong, M. L. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119846 · Cited by 220 · cited 1×
“Nevertheless, peripheral blockade does not impair the direct sensitivity of the brain to centrally produced immune signals [48,49].”
BackgroundMiyaoka, T., Wake, R., Furuya, M., Liaury, K., Ieda, M., Kawakami, K., Tsuchie, K., Taki, M., Ishihara, K., Araki, T., et al. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.02.002 · Cited by 212
O'Donovan, A., Rush, G., Hoatam, G., Hughes, B. M., McCrohan, A., Kelleher, C., O'Farrelly, C., & Malone, K. M. (2013) · Depression and Anxiety · doi:10.1002/da.22087 · Cited by 210
Frodl, T., Carballedo, A., Hughes, M. M., Saleh, K., Fagan, A., Skokauskas, N., McLoughlin, D. M., Meaney, J., O'Keane, V, & Connor, T. J. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.14 · Cited by 176
Karlović, D., Serretti, A., Vrkić, N., Martinac, M., & Marčinko, D. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2011.12.007 · Cited by 175
Interleukin 6 in autoimmune and inflammatory diseases: a personal memoir
HIRANO, T. (2010) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.86.717 · Cited by 172 · cited 1×
“The TH17 subset is involved in chronic inflammation and autoimmunity via secretion of IL-17 and other inflammatory cytokines, whereas Treg cells limit T-cell responses to protect against autoimmunity and excessive tissue damage [24,25].”
BackgroundCapuron, L., Fornwalt, F. B., Knight, B. T., Harvey, P. D., Ninan, P. T., & Miller, A. H. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.02.017 · Cited by 164
Li, Y., Xiao, B., Qiu, W., Yang, L., Hu, B., Tian, X., & Yang, H. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.10.018 · Cited by 163
Differences in cytokines between non-suicidal patients and suicidal patients in major depression
Kim, Y.-K., Lee, S.-W., Kim, S.-H., Shim, S.-H., Han, S.-W., Choi, S.-H., & Lee, B.-H. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.08.041 · Cited by 140
A Preliminary Study of Cytokines in Suicidal and Nonsuicidal Adolescents with Major Depression
Gabbay, V., Klein, R. G., Guttman, L. E., Babb, J. S., Alonso, C. M., Nishawala, M., Katz, Y., Gaite, M. R., & Gonzalez, C. J. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.0140 · Cited by 136 · cited 1×
“[81] MDD + high SI (n = 29), MDD + low SI (n = 45), nondepressed HC (n = 48) Higher IL-6 in MDD + high SI versus MDD + low SI or HC [74,82] [185,186]”
MethodMartinez, J. M., Garakani, A., Yehuda, R., & Gorman, J. M. (2012) · Depression and Anxiety · doi:10.1002/da.20876 · Cited by 131
Stimulatory effect of antidepressants on the production of IL-6
Kubera, M., Kenis, G., Bosmans, E., Kajta, M., Basta-Kaim, A., Scharpe, S., Budziszewska, B., & Maes, M. (2004) · International Immunopharmacology · doi:10.1016/j.intimp.2003.11.006 · Cited by 126 · cited 2×
“However, the anti-inflammatory effects of antidepressants are inconsistent, with some studies reporting treatment-induced elevations of IL-6 [115], while others report nonsignificant changes (Table 2) [64,116].”
ResultJazayeri, S., Keshavarz, S. A., Tehrani-Doost, M., Djalali, M., Hosseini, M., Amini, H., Chamari, M., & Djazayery, A. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2009.04.013 · Cited by 116 · cited 1×
“[193] Zinc sulfate (25 mg/day) + SSRI (n = 20), placebo + SSRI (n = 17) NS difference in plasma IL-6 levels between treatment groups [194] EPA 1000 mg (n = 14), EPA 1000 mg + fluoxetine 20 mg (n = 14), fluoxetine 20 mg (n = 14) NS post-treatment changes in serum IL-6 levels from baseline”
BackgroundDissociation of inflammatory markers and natural killer cell activity in major depressive disorder
Pike, J. L., & Irwin, M. R. (2006) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2005.05.004 · Cited by 101 · cited 1×
“[173] MDD (n = 48), HC (n = 63) Higher serum IL-6 levels in MDD versus HC [64,174-178] [179,180] [181] MDD (n = 20), HC (n = 22) Higher IL-6 mRNA in MDD versus HC [64] MDD (n = 77), HC (n = 38) Higher plasma sIL-6R in MDD versus HC [77] [79] MDD (n = 40) IL-6 levels positively associated with depression severity [80,8…”
BackgroundDunjic-Kostic, B., Ivkovic, M., Radonjic, N. V., Petronijevic, N. D., Pantovic, M., Damjanovic, A., Poznanovic, S. T., Jovanovic, A., Nikolic, T., & Jasovic-Gasic, M. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.11.009 · Cited by 99 · cited 2×
“[187] MDD (n = 257), HC (n = 105) NS difference in genotype and allele frequency for IL-6 promoter variant between groups [84] Melancholic MDD (n = 29), atypical MDD (n = 18), HC (n = 39) Higher IL-6 in melancholic* but not atypical MDD versus HC [85]* [188]”
BackgroundDepression, traumatic stress and interleukin-6
Bob, P., Raboch, J., Maes, M., Susta, M., Pavlat, J., Jasova, D., Vevera, J., Uhrova, J., Benakova, H., & Zima, T. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.03.017 · Cited by 97 · cited 2×
“Preliminary evidence indicates that circulating IL-6 concentrations are associated with depression severity [79,80].”
BackgroundCitalopram reduces endotoxin-induced fatigue
Hannestad, J., DellaGioia, N., Ortiz, N., Pittman, B., & Bhagwagar, Z. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.10.013 · Cited by 95
Ranjbar, E., Shams, J., Sabetkasaei, M., M-Shirazi, M., Rashidkhani, B., Mostafavi, A., Bornak, E., & Nasrollahzadeh, J. (2014) · Nutritional Neuroscience · doi:10.1179/1476830513y.0000000066 · Cited by 92
Smith, A. K., Simon, J. S., Gustafson, E. L., Noviello, S., Cubells, J. F., Epstein, M. P., Devlin, D. J., Qiu, P., Albrecht, J. K., Brass, C. A., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.67 · Cited by 84
Patas, K., Penninx, B. W. J. H., Bus, B. A. A., Vogelzangs, N., Molendijk, M. L., Elzinga, B. M., Bosker, F. J., & Oude Voshaar, R. C. (2014) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2013.10.007 · Cited by 80 · cited 1×
“[189] MDD (n = 1070), nondepressed HC (n = 379) IL-6 levels positively associated with brainderived neurotrophic factor levels in MDD [190] MDD + MetS (n = 66), MDD + no MetS (n = 79) Higher IL-6 levels in MDD patients with versus without metabolic syndrome [191]”
BackgroundCerebrospinal fluid interleukin (IL)-6 in unipolar major depression
Carpenter, L. L., Heninger, G. R., Malison, R. T., Tyrka, A. R., & Price, L. H. (2004) · Journal of Affective Disorders · doi:10.1016/s0165-0327(02)00460-3 · Cited by 79
Rudolf, S., Greggersen, W., Kahl, K. G., Hüppe, M., & Schweiger, U. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.02.016 · Cited by 71 · cited 1×
“In particular, studies have observed elevated IL-6 among patients with atypical [83] and melancholic [84,85] depression.”
BackgroundRole of cytokines in atypical depression
Yoon, H.-K., Kim, Y.-K., Lee, H.-J., Kwon, D.-Y., & Kim, L. (2012) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2011.611894 · Cited by 65 · cited 1×
“[187] MDD (n = 257), HC (n = 105) NS difference in genotype and allele frequency for IL-6 promoter variant between groups [84] Melancholic MDD (n = 29), atypical MDD (n = 18), HC (n = 39) Higher IL-6 in melancholic* but not atypical MDD versus HC [85]* [188]”
BackgroundStübner, S., Schön, T., Padberg, F., Teipel, S. J., Schwarz, M. J., Haslinger, A., Buch, K., Dukoff, R., Lasser, R., Müller, N., et al. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00916-1 · Cited by 59
Acetylsalicylic acid as an augmentation agent in fluoxetine treatment resistant depressive rats
Wang, Y., Yang, F., Liu, Y.-F., Gao, F., & Jiang, W. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.05.035 · Cited by 56
Inflammatory Biomarkers in Depression: An Opportunity for Novel Therapeutic Interventions
Li, M., Soczynska, J. K., & Kennedy, S. H. (2011) · Current Psychiatry Reports · doi:10.1007/s11920-011-0210-6 · Cited by 53 · cited 2×
“These improvements in depressive-like symptoms were associated with normalization of central monoaminergic neurotransmitter systems, including serotonin, noradrenaline and dopamine [139], and blockade of stress-induced reductions of BDNF [140].”
BackgroundSelf-citationGarcia-Oscos, F., Peña, D., Housini, M., Cheng, D., Lopez, D., Borland, M. S., Salgado-Delgado, R., Salgado, H., D’Mello, S., Kilgard, M. P., et al. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.07.020 · Cited by 43
Fatigue in patients with advanced cancer: a pilot study of an intervention with infliximab
Tookman, A. J., Jones, C. L., DeWitte, M., & Lodge, P. J. (2008) · Supportive Care in Cancer · doi:10.1007/s00520-008-0429-x · Cited by 41 · cited 1×
“Similar improvements in secondary outcome measures of depression and quality of life have also been observed in individuals with inflammatory disorders treated with TNF antagonists [128-130].”
Result
Cited by
Zhang, J.-C., Yao, W., & Hashimoto, K. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160119094646 · Cited by 538
“This makes it unlikely that brain-derived IL-6 might be involved in the pathogenesis of depression [63, 64].”
Role of IL-6 in the regulation of neuronal development, survival and function
Kummer, K. K., Zeidler, M., Kalpachidou, T., & Kress, M. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155582 · Cited by 278
Role of Inflammation in Suicide: From Mechanisms to Treatment
Brundin, L., Bryleva, E. Y., & Thirtamara Rajamani, K. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.116 · Cited by 257
“Previous studies have found that tocilizumab is able to effectively treat several inflammatory and autoimmune diseases (Choy et al , 2002; Fonseka et al , 2015; Ito et al , 2004) and a recently initiated RCT will access the ability of tocilizumab to decrease depressive symptomology in…”
Zhang, J.-C., Yao, W., Dong, C., Yang, C., Ren, Q., Ma, M., & Hashimoto, K. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.112 · Cited by 182
Atli, A., Demir, S., Bulut, M., Okan İbiloğlu, A., Güneş, M., Kaya, M., Demirpençe, Ö., & Sır, A. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s89470 · Cited by 156
Metadata
- Authors
- Fonseka, T. M., McIntyre, R. S., Soczynska, J. K., & Kennedy, S. H.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2015-01-14
- Volume
- 24
- Issue
- 4
- Pages
- 459-475
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2129376177
- Cited by
- 54
- References
- 77
- FWCI
- 5.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.